The Gaithersburg, Md-based drugmaker will use the funding to speed the production of 100 million doses of its vaccine by the beginning of 2021. Novavax has never brought f a product to market, but the candidate employs the same technology as its other experimental vaccines that have gone through late-stage testing.
Results from the vaccine’s May safety trials in Australia are expected to be available in July, and Novavax plans to begin phase 3 efficacy testing during this fall.
“Adding Novavax’s candidate to Operation Warp Speed’s diverse portfolio of vaccines increases the odds that we will have a safe, effective vaccine as soon as the end of this year,” HHS Secretary Alex Azar said in a July 7 news release.
More articles on pharmacy:
Drug lobby sues Minnesota over insulin-pricing law
Regeneron begins late-stage testing of COVID-19 antibody treatment
Early use of hydroxychloroquine reduced COVID-19 deaths, study says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
